Novartis Pauses Autoimmune Cell Therapy Trials After Three Deaths

What happened

Novartis has paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders after three patient deaths, according to a Wall Street Journal report. The therapy, which was being evaluated in a range of conditions, is now under investigation, and the company has not disclosed the specific cause of the deaths or the timeline for resuming trials. This development is not reflected in the latest DeepValue master report, which focused on Novartis's core growth brands and near-term catalysts such as Pluvicto and pelacarsen. The pause introduces a new safety concern for a pipeline asset that was not previously highlighted as a major value driver. While the full financial impact is unclear, the event adds to execution risks during a period when Novartis is already managing a patent cliff and relying on pipeline success to sustain its premium valuation.

Implication

Investors should await further information on the paused program, including the nature of the deaths and whether the therapy can be salvaged with protocol modifications. This event increases the risk profile of Novartis's cell therapy ambitions, though it does not directly affect the near-term catalysts that are central to the current investment thesis. The existing WAIT rating remains appropriate, as the stock was already trading near fair value with limited margin of safety. Any sustained decline below $140 could provide a more attractive entry, but only if the broader pipeline remains intact. Balance sheet strength provides some cushion, but repeated pipeline setbacks could erode the premium multiple.

Thesis delta

The pause of eight trials due to patient deaths adds a new layer of clinical risk to Novartis's pipeline, particularly in the autoimmune and neurology space. While this specific asset was not a key near-term catalyst, it underscores the inherent uncertainty in early-stage development and may temper enthusiasm for the company's innovation narrative. The thesis remains WAIT, but the probability of the bear scenario increases slightly.